<DOC>
	<DOC>NCT02328807</DOC>
	<brief_summary>The main purpose of this study is to evaluate the safety and efficacy of focal (targeted) Radio-Frequency Ablation (RFA) in men with low or intermediate-risk, clinically localized prostate cancer.</brief_summary>
	<brief_title>Focal Prostate Radio-Frequency Ablation</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Men 18 years of age or older Diagnosis of adenocarcinoma of the prostate, confirmed by H.L. Moffitt Cancer Center review No prior treatment for prostate cancer Eastern Cooperative Oncology Group (ECOG) performance status of 0 or1 Prostate Cancer Clinical Stage T2a and below PSA &lt;10 ng/ml (this will be the prostatic specific antigen (PSA) level prompting the initial prostate biopsy) Prostate size &lt;60 cc on transrectal ultrasound Preenrollment biopsy parameters (as per H.L. Moffitt C.C. review): Minimum of 10 biopsy cores; Gleason score 6 aor 7; Unilateral cancer (only rightsided or leftsided, not bilateral). Men less than 18 years of age Medically unfit for anesthesia Histology other than adenocarcinoma Biopsy does not meet inclusion criteria Men who have received any hormonal manipulation (antiandrogens; Luteinizing Hormone Releasing Hormone (LHRH) agonist; 5alphareductase inhibitors) within the previous 6 months</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>adenocarcinoma</keyword>
	<keyword>prostate</keyword>
	<keyword>ENCAGEâ„¢</keyword>
	<keyword>focal bipolar radiofrequency ablation</keyword>
	<keyword>radiofrequency ablation (RFA)</keyword>
	<keyword>radiotherapy</keyword>
</DOC>